Abstract

The syndromes caused by frontotemporal lobar degeneration have highly heterogeneous and overlapping clinical features. There has been great progress in the refinement of clinical diagnostic criteria in the past decade, but we propose that a better understanding of aetiology, pathophysiology and symptomatic treatments can arise from a transdiagnostic approach to clinical phenotype and brain morphometry. In a cross-sectional epidemiological study, we examined 310 patients with a syndrome likely to be caused by frontotemporal lobar degeneration, including behavioural variant frontotemporal dementia, non-fluent, and semantic variants of primary progressive aphasia (PPA), progressive supranuclear palsy and corticobasal syndrome. We included patients with logopenic PPA and those who met criteria for PPA but not a specific subtype. To date, 49 patients have a neuropathological diagnosis. A principal component analysis identified symptom dimensions that broadly recapitulated the core features of the main clinical syndromes. However, the subject-specific scores on these dimensions showed considerable overlap across the diagnostic groups. Sixty-two per cent of participants had phenotypic features that met the diagnostic criteria for more than one syndrome. Behavioural disturbance was prevalent in all groups. Forty-four per cent of patients with corticobasal syndrome had progressive supranuclear palsy-like features and 30% of patients with progressive supranuclear palsy had corticobasal syndrome-like features. Many patients with progressive supranuclear palsy and corticobasal syndrome had language impairments consistent with non-fluent variant PPA while patients with behavioural variant frontotemporal dementia often had semantic impairments. Using multivariate source-based morphometry on a subset of patients (n = 133), we identified patterns of covarying brain atrophy that were represented across the diagnostic groups. Canonical correlation analysis of clinical and imaging components found three key brain-behaviour relationships, with a continuous spectrum across the cohort rather than discrete diagnostic entities. In the 46 patients with follow-up (mean 3.6 years) syndromic overlap increased with time. Together, these results show that syndromes associated with frontotemporal lobar degeneration do not form discrete mutually exclusive categories from their clinical features or structural brain changes, but instead exist in a multidimensional spectrum. Patients often manifest diagnostic features of multiple disorders while deficits in behaviour, movement and language domains are not confined to specific diagnostic groups. It is important to recognize individual differences in clinical phenotype, both for clinical management and to understand pathogenic mechanisms. We suggest that a transdiagnostic approach to the spectrum of frontotemporal lobar degeneration syndromes provides a useful framework with which to understand disease aetiology, progression, and heterogeneity and to target future treatments to a higher proportion of patients.

Highlights

  • The clinical disorders caused by frontotemporal lobar degeneration pathologies (FTLD) are highly heterogeneous in their pathology and phenotypes (Kertesz et al, 2005; MacKenzie et al, 2010; Rohrer et al, 2011)

  • We assessed in person 85% (310/365) of the patients identified as living in the study catchment area with a FTLD syndrome

  • 44% of corticobasal syndrome (CBS) patients expressed this pattern to the same degree as progressive supranuclear palsy (PSP) patients

Read more

Summary

Introduction

The clinical disorders caused by frontotemporal lobar degeneration pathologies (FTLD) are highly heterogeneous in their pathology and phenotypes (Kertesz et al, 2005; MacKenzie et al, 2010; Rohrer et al, 2011). BvFTD can be associated with tau, TDP-43, FUS protein inclusions or mixed neuropathology (Perry et al, 2017). Some clinical syndromes, such as PSP-Richardson’s syndrome, have good correlation with the associated pathology (Gazzina et al, 2019); the corresponding pathology may have diverse phenotypic expressions (Respondek et al, 2014). Recent revisions of diagnostic criteria recognize this heterogeneity (Armstrong et al, 2013; Hoglinger et al, 2017), and there may be future improvements in clinicopathological correlations by imaging or fluid-based biomarkers, aiming to optimize patient selection for disease-modifying therapies (Irwin et al, 2015; Meeter et al, 2017)

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.